Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$16.10 USD
-0.30 (-1.83%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $16.43 +0.33 (2.05%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
VRNA 16.10 -0.30(-1.83%)
Will VRNA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRNA
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Ligand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
Wall Street Analysts Believe Verona Pharma PLC American Depositary Share (VRNA) Could Rally 135.87%: Here's is How to Trade
Other News for VRNA
Piper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)
Verona Pharma price target raised by $5 at Piper Sandler, here's why
Sanofi and Regeneron’s Dupixent set for large gains with likely COPD approval
Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy
Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine’s Expected FDA Approval and Strong Financial Standing